Who Paid My Doc
Mark Karolak
Facial Plastic Surgery Brick, NJ Doctor of Osteopathy
NPI 1063482651 CMS profile 1247259
208 Jack Martin Blvd, Brick, NJ 08724
General payments
$331
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Karolak of Brick, NJ is reported in the CMS Open Payments database as having received $331 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 22nd percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $60 | 1 | |
| 2024 | General | $159 | 2 | |
| 2021 | General | $39 | 3 | |
| 2020 | General | $25 | 2 | |
| 2019 | General | $49 | 4 |
Beside peers
- Mark Karolak
- Facial Plastic Surgery median
- Middle half of Facial Plastic Surgery
- National median
In program year 2025, general payments to Mark Karolak were reported at $60. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.
Show as a table
| Year | Mark Karolak | Facial Plastic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $49 | $225 | $92–$651 | $163 |
| 2020 | $25 | $132 | $45–$323 | $114 |
| 2021 | $39 | $186 | $67–$558 | $132 |
| 2022 | $0 | $218 | $83–$594 | $149 |
| 2023 | $0 | $237 | $94–$564 | $160 |
| 2024 | $159 | $233 | $104–$575 | $164 |
| 2025 | $60 | $270 | $116–$579 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
40
Drug cost
$184
Branded share of claims
30%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cefadroxil | Generic | 16 | $102 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 12 | $48 | |
| Ondansetron Hcl | Generic | 12 | $34 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Facial Plastic Surgery in New Jersey
Jeffrey Wise
Facial Plastic Surgery · Wayne, NJ
Tanveer Janjua
Facial Plastic Surgery · Bedminster, NJ
Reynaldo Paraiso
Facial Plastic Surgery · West Orange, NJ
Ronald Iannacone
Facial Plastic Surgery · Manasquan, NJ
John Scheibelhoffer
Facial Plastic Surgery · Wayne, NJ
Thomas Brandeisky
Facial Plastic Surgery · Brick, NJ
Related records
Facial Plastic Surgery in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Facial Plastic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.